PMID- 25867537
OWN - NLM
STAT- MEDLINE
DCOM- 20151201
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 31
IP  - 6
DP  - 2015 Jun
TI  - Prospective cohort study of clinical characteristics and management patterns for 
      patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.
PG  - 1117-27
LID - 10.1185/03007995.2015.1036015 [doi]
AB  - BACKGROUND: Lung cancer is a major cause of mortality in Russia. This study aimed 
      to document the characteristics, clinical management, EGFR mutation status and 
      outcomes of patients with non-small-cell lung cancer (NSCLC) throughout the 
      Russian Federation to inform future management decisions. METHODS: This 
      non-interventional, prospective cohort study (clinicaltrials.gov NCT01069835) was 
      conducted at 33 sites across the Russian Federation. Patients with confirmed 
      NSCLC were enrolled and followed for up to 12 months or until death. 
      Investigators collected information on patient and disease characteristics, 
      diagnosis and treatment patterns, clinical outcomes and adverse events (AEs). A 
      logistic regression model was used to evaluate characteristics affecting tumor 
      EGFR mutation status. RESULTS: Data were analyzed from 838 patients. Most (78.4%) 
      were male and Caucasian (98%), mean age was 58.7 years and 26.5% were 
      never-smokers. Squamous-cell carcinoma (54.3%) was the most prevalent histology, 
      followed by adenocarcinoma (31%). Most patients presented with advanced disease 
      (23.7% with stage IIIA, 14.1% with stage IIIB, 25.4% with stage IV) and 10.1% of 
      patients had EGFR-mutation-positive tumors. EGFR mutation was significantly 
      associated with female gender, never smoking, age and adenocarcinoma histology. 
      First- or second-line chemotherapy had been performed in 370 and 96 patients, 
      respectively, and median progression-free survival was 35 and 19.4 weeks, 
      respectively. For 813 patients, 194 AEs were reported at visit 1. A median of two 
      AEs was reported for patients who had at least one AE. Study limitations include 
      potential site selection bias, short observation period, small sample size and 
      inclusion of fewer than average stage III-IV patients. CONCLUSIONS: This study 
      contributes to a better understanding of prognostic and predictive factors of 
      NSCLC in the Russian Federation, which will enable optimal treatment selection in 
      future clinical practice. Epidemiology of EGFR mutations in this NSCLC cohort was 
      similar to other studies of NSCLC in Caucasian populations.
FAU - Tjulandin, S
AU  - Tjulandin S
AD  - Russian Cancer Research Centre, Department of Clinical Pharmacology and 
      Chemotherapy , Moscow , Russian Federation.
FAU - Imyanitov, E
AU  - Imyanitov E
FAU - Moiseyenko, V
AU  - Moiseyenko V
FAU - Ponomarenko, D
AU  - Ponomarenko D
FAU - Gurina, L
AU  - Gurina L
FAU - Koroleva, I
AU  - Koroleva I
FAU - Karaseva, V
AU  - Karaseva V
LA  - eng
SI  - ClinicalTrials.gov/NCT01069835
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150508
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma/drug therapy/genetics/pathology
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology
MH  - Carcinoma, Squamous Cell/drug therapy/genetics/pathology
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Prognosis
MH  - Prospective Studies
MH  - Russia
OTO - NOTNLM
OT  - Disease management
OT  - EGFR mutation
OT  - NSCLC
OT  - Russian Federation
OT  - Therapeutic interventions
OT  - Treatment outcomes
EDAT- 2015/04/14 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/04/14 06:00
PHST- 2015/04/14 06:00 [entrez]
PHST- 2015/04/14 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1185/03007995.2015.1036015 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2015 Jun;31(6):1117-27. doi: 10.1185/03007995.2015.1036015. 
      Epub 2015 May 8.